AllSight
Companies · OMER · Pharmaceutical Preparations

OMEROS CORP (OMER)

OMEROS CORP (OMER) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

OMEROS CORP (OMER) stock — financials & valuation

Key numbers for OMEROS CORP (OMER): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 47/100 — a percentile rank of OMEROS CORP’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$1.3B
P / E10.7×
P / S34.8×
EV / EBITDA-19.6×
Gross margin96.4%
Operating margin-189.5%
Net margin324.9%
Return on equity-243.1%
ROIC-358.5%
Debt / equity-1.4×
Dividend yield0.0%

Is OMEROS CORP overvalued? P/E looks fair vs its 5-year range.

Independent of the events above — derived from OMEROS CORP’s own financial statements and shown as context, never as advice.

Aug 12, 2026Beat
YARTEMLEA just cleared the commercial hurdle Omeros needed most
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact